Gain Therapeutics (NASDAQ:GANX) Price Target Cut to $8.00 by Analysts at HC Wainwright

Gain Therapeutics (NASDAQ:GANX) had its price objective reduced by HC Wainwright from $9.00 to $8.00 in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms also recently weighed in on GANX. Oppenheimer reiterated an outperform rating and issued a $9.00 price target on shares of Gain Therapeutics in a research report on Tuesday, April 23rd. Chardan Capital restated a buy rating and set a $6.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, March 27th.

Gain Therapeutics Trading Up 6.7 %

Shares of NASDAQ:GANX opened at $1.20 on Tuesday. Gain Therapeutics has a 12-month low of $1.11 and a 12-month high of $5.33. The stock has a market cap of $21.57 million, a PE ratio of -0.80 and a beta of 0.35. The business has a 50 day moving average of $2.23 and a 200-day moving average of $3.27. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. As a group, equities research analysts forecast that Gain Therapeutics will post -1.11 earnings per share for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.